

PROLENSA™
*(bromfenac ophthalmic
solution) 0.07%*

BAUSCH+LOMB

Agenda

- Disease State and Market Overview
- Product Overview
- Summary

PROLENSA™
*(brimonidine ophthalmic
solution) 0.07%*

2

BAUSCH + LOMB

Disease State and Market Overview

PROLENSA[®]
*(propranolol ophthalmic
solution) 0.07%*

BAUSCH + LOMB

Disease State Overview

- Approximately 6 million ocular anti-inflammatory prescriptions (steroid and NSAID) were written for post surgery in 2011
 - 3.5 million cataract surgeries are projected for 2013²
- Although surgeries have advanced to be minimally invasive, some degree of postoperative inflammation is still unavoidable³
 - Direct ocular manipulation causes the release of prostaglandins and other inflammatory mediators from the iris and ciliary body
- NSAIDs are commonly used to treat postoperative inflammation and reduce ocular pain
- Anti-inflammatory agents post surgery allow for more rapid resolution of inflammatory symptoms⁴


References: 1. IMS Health National Prescription Audit, July MAT. 2. Market Scope 2012 Report on Global IOL Market. 3. Lane S. *Refractive Eyecare*. 2009. 4. The Loteprednol Etabonate Postoperative Inflammation Study Group. 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. *Ophthalmology*. 1998;105(9):1780-1786.

PROLENSA[®]
*(bromfenac ophthalmic
solution) 0.07%*

4

BAUSCH+LOMB

Cataract Procedures



- The US population aged 65 years and older increased from 35 million in 2000 to 40 million in 2010 (a 15% increase) and is estimated to reach 55 million by 2020 (a 36% increase). By 2030, the elderly population will reach 72.1 million—almost twice the number in 2007 and roughly 20% of the US population^{2*}

* According to current data provided by the US Census Bureau

References: 1. Market Scope 2012 Report on Global IOL Market. 2. The U.S. older population reaches a new zenith as baby boomers turn 65. Administration on Aging Web site: http://www.aos.gov/AoA/ocof/Press_Room/Social_Media/Widget/Statistical_Profile/2010/3.aspx. Modified May 12, 2010. Accessed April 2, 2013.

PROLENSA[™]
(bromfenac ophthalmic solution) 0.07%

5

BAUSCH + LOMB

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.